REVIEW Nebivolol is a chiral, selective, third-generation beta1-receptor antagonist used in the treatment of hypertension and chronic heart failure. It blocks activation of adrenergic receptors by epinephrine, reversing its effects and lowering heart rate and blood pressure. It has additional nitric oxide-mediated vasodilating and antioxidant properties, along with a favorable metabolic profile.
REFERENCES
[1]
Noe, Christian R.; Jasic, Muhamed; Kollmann, Hermann; Lachmann, Bodo Process for preparation of Nebivolol using 6-fluoro-3,4-dihydrobenzopyran-2-carboxaldehyde cyanohydrins. PCT Int. Appl. (2007), WO 2007009143 A2 20070125.
[2]
Khamar, Bakulesh Mafatlal; Thakor, Indrajit; Patel, Mahesh; Jadav, Kalpesh; Parikh, Ankur; Joshi, Atul Chhotalal; Ponnaiah, Ravi; Modi, Indravadan Ambalal An improved process for the preparation of nebivolol hydrochloride Eur. Pat. Appl. (2010), EP 2163551 A1 20100317.
[3]
Maragni, Paolo; Michieletto, Ivan; Volpicelli, Raffaella; Soriato, Giorgio; Foletto, Johnny; Cotarca, Livius; Verzini, Massimo Process for preparing nebivolol PCT Int. Appl. (2010), WO 2010049455 A1 20100506.
[4]
Gielen W, Cleophas TJ, Agrawal R: Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57.
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information.
Add to Favorites 
Delete from Favorites 
